Skip to content

Lifestyle program showed regional brain blood-flow differences in early Alzheimer's disease

A small interim analysis found regional differences, while whole-brain blood flow and a diabetes-risk index did not differ between groups.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

This abstract-based analysis found higher blood flow in selected brain regions in the active group, without a between-group difference in whole-brain blood flow or the QUICKI diabetes-risk index. Greater adherence was associated with better regional blood flow and QUICKI results, but that association does not establish that adherence caused the differences.

Keep in mind

The sample was small, and this was a mid-trial analysis. The abstract reports physiological markers without cognitive outcomes or effect sizes, limiting conclusions about symptom improvement or Alzheimer's disease progression.

THE RESULT, WITH CONTEXT

What researchers found

Higher regional blood flow

ASL-MRI brain blood-flow measurement

Active program versus control at the reported post-trial assessment; whole-brain blood flow did not differ. Effect sizes were not given.

J Alzheimers Dis, 2025 · Original source ↓

What differed between groups

Both groups received recommendations and medical care. The active group also received coaching, exercise training, and supplements. Because these additions were bundled together, the comparison cannot identify which component accounted for regional blood-flow differences.

Adherence is a separate analysis

People with higher adherence scores had better regional blood-flow results and improved QUICKI scores. However, adherence itself did not differ between trial arms, and these adherence associations should be distinguished from the intervention comparison.

CHECK THE ORIGINAL

The original publication

A multi-modal medical management and lifestyle intervention increase cerebral blood flow and lowers diabetic risk in persons with early Alzheimer's disease: Mid-trial results from the PREVENTION trial.

Bramen JE, Siddarth P, Popa ES et al.
J Alzheimers Dis · 2025

PubMed ID
41243261
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.